Compare Neurocrine Biosciences Inc (NBIX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Yum! Brands, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.9 (market cap $15.77B), while Yum! Brands, Inc. trades at $144.94 (market cap $39.61B). The key difference: Yum! Brands, Inc. is far larger — about 2.5× Neurocrine Biosciences Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | YUM | |
|---|---|---|
Market Cap | $15.77B | $39.61B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $168.16 |
52-Week Low | $123.10 | $138.21 |
Enterprise Value | $15.78B | $51.22B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
YUM trades at $149.59, down 0.74% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.21B in 2025, with net income of $1.56B and a net margin of 25.4%. Recent developments include the sale of Pizza Hut for approximately $1.5B to LongRange Capital, completed on September 1, 2026, and a declared quarterly dividend of $0.75 per share. Analyst consensus is a buy rating with a price target of $173.60, though technical indicators suggest near-term caution.
Outlook remains supported by strong profitability and strategic portfolio optimization, but risks include high debt levels and competitive pressures. The stock offers potential upside to the consensus target, yet investor sentiment is mixed amid broader market volatility and recent insider selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
